the aid library

LIST OPTIONS

Filter

14836

Download (325)

View PDF (330)

HEARTS. Accès aux médicaments essentiels et aux technologies de santé de base

Organisation Mondiale de la Santé OMS, et al. (2018) C_WHO

Guide technique pour la prise en charge des maladies cardiovasculaires dans le cadre des soins de santé primaires

External Link

Acute Chagas Disease: New Global Challenges for an Old Neglected Disease

Andrade, D.; Gollob, K.; Dutra, W. PLoS Neglected Tropical diseases (2015) CC

Abstract: Chagas disease is caused by infection with the protozoan Trypanosoma cruzi, and although over 100 years have passed since the discovery of Chagas disease, it still presents an increasing problem for global public health. A plethora of information concerning the chronic phase of human Chaga... more

Download (1020)

View PDF (929)

Namibia: Nutrition guidelines for prevention and management of non-communicable diet related disease

Ministry of Health and Social Services (MOHSS) (2013) C1

External Link

Questions and Answers for Obstetrical Healthcare Providers: Pregnant Women and Zika Virus Infection

Centers for Disease Control and Prevention CDC (2022) C_CDC

English version

Download (189)

View PDF (233)

Reflection on inclusive health services in northwest Syria (NWS)

Islamic Relief (2022) CC

After a decade of crisis, Syria remains one of the world’s most complex humanitarian crises. Continued hostilities, new and protracted displacement, increased returns and the sustained destruction of communities have impacted Syrians’ lives and futures in a devastating way. The 2021 Humanitarian... more

Download (1595)

View PDF (4670)

Gestion des déchets produits par les injections au niveau des districts

Organisation Mondiale de la Santé OMS (2006) CC

Le présent guide a été conçu comme un outil simple et pratique pour aider les administrateurs sanitaires des districts à élaborer un plan réaliste à leur niveau, afin de mieux gérer l'élimination des déchets produits par les injectio

External Link

The achievement of a storytelling about Chagas disease: how to talk about silence; how to visualise the invisible

Mas, F. National Library of Medicine (2022) CC

Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 117: e220083chgsa, 2022 Two adjectives raise an issue for communicators working on Chagas disease (CD): “invisible and silent”. Two adjectives that can be ascribed to other neglected tropical diseases (NTD), but which are part of the essence of CD. Br... more

External Link

Guide to introducing human rabies vaccine into national immunization programmes: Handbook

World Health Organization WHO (2022) C_WHO

Rabies is fatal, vaccine-preventable disease responsible for an estimated 59,000 human deaths each year. Most cases are transmitted by dogs, and most deaths occur in underserved populations in Africa and Asia. Approximately 40% of deaths occur in children.

External Link

Mycetoma: epidemiology, treatment challenges, and progress

Taha, H.; Fahal, A.; Van de Sande, W. Dovepress open access to scientific and medical research (2015) CC

Mycetoma is a specific chronic, granulomatous, inflammatory disease. It usually involves the subcutaneous tissue, most probably after traumatic inoculation of the causative organism. It has a prolonged, progressive, and indolent course, and, if untreated, it ultimately leads to destruction of the de... more

Download (590)

View PDF (1631)

Framework for a national plan for monitoring and management of insecticide resistance in malaria vectors

World Health Organization (WHO) (2017) C_WHO

Effective malaria prevention is threatened by widespread and increasing vector insecticide resistance. Failure to mitigate this threat will likely result in an increased burden of disease, with significant cost implications. This new framework provides support for the development of a national insec... more

Download (185)

View PDF (216)

Adolescent Girls in Disaster & Conflict: Interventions for Improving Access to Sexual and Reproductive Health Services

S. Guthridge-Gould UNFPA (United Nations Population Fund) (2016) C2

Download (764)

View PDF (1571)

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstratio

World Health Organization (2012)

Download (1376)

View PDF (1561)

Basic Epidemiology

Bonita, R.; R.Beaglehole, and T. Kjellström World Health Organization WHO (2006) C_WHO

2nd edition

Download (205)

View PDF (241)

EMTCT Plus - Framework for Elimination of Mother-to-Child Transmission of HIV, Syphilis, Hepatitis B, and Chagas

F. Pérez; M. B. Mello; L. Sereno; et al. Pan American Health Organization; World Health Organization (2017) C_WHO

The objective of the EMTCT Plus initiative is to achieve and sustain the elimination of mother-to-child transmission of HIV, syphilis, Chagas, and perinatal hepatitis B (HBV) as a public health threat. It embraces the principles and lines of action of the Strategy for Universal Access to Health a... more

Download (350)

View PDF (490)

Community Ear & Hearing Health - Volume 9 • Issue 12 (2012)

Community Ear & Hearing Health (2012) C2

This journal is funded by CBM

Download (346)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (242)

View PDF (291)

Plan de mise en œuvre et cadre de suivi et d’évaluation du Cadre d’action européen de l’OMS visant à permettre aux personnes handicapées d’atteindre le meilleur état de santé possible 2022-2030

World Health Organisation (WHO) (2023) C_WHO

Le « Cadre d’action européen de l’OMS visant à permettre aux personnes handicapées d’atteindre le meilleur état de santé possible 2022-2030 » proposé a été élaboré en concertation avec les États membres de la Région européenne de l’OMS et réaffirmé lors de multiples concerta... more